

Prescriber Criteria Form

Xgeva BDC 2024 PA Fax 637-A BD-13 v1 010124.docx
 Xgeva (denosumab)
 Coverage Determination

This fax machine is located in a secure location as required by HIPAA regulations.
 Complete/review information, sign and date. Fax signed forms to CVS Caremark at **1-855-633-7673**.
 Please contact CVS Caremark at **1-866-785-5714** with questions regarding the prior authorization process.
 When conditions are met, we will authorize the coverage of Xgeva (denosumab).

Drug Name:
 Xgeva (denosumab)

| | | |
|----------------------------|------------------------|-------------|
| Patient Name: | | |
| Patient ID: | | |
| Patient DOB: | Patient Phone: | |
| Prescriber Name: | | |
| Prescriber Address: | | |
| City: | State: | Zip: |
| Prescriber Phone: | Prescriber Fax: | |
| Diagnosis: | ICD Code(s): | |

Please circle the appropriate answer for each question.

B vs D CRITERIA FOR DETERMINATION

| | | | |
|---|--|-----|----|
| 1 | Is the requested drug being supplied from the practitioner and/or office stock supply and billed as part of a practitioner service (i.e., the drug is being furnished "incident to a practitioner's service")? [If yes, then no further questions.] | Yes | No |
|---|--|-----|----|

CRITERIA FOR APPROVAL

| | | | |
|---|--|-----|----|
| 2 | Does the patient have giant cell tumor of the bone? [If yes, then no further questions.] | Yes | No |
| 3 | Is the requested drug being prescribed for the prevention of skeletal-related events due to multiple myeloma or bone metastases from solid tumors? [If yes, then no further questions.] | Yes | No |
| 4 | Does the patient have hypercalcemia of malignancy? [If no, then no further questions.] | Yes | No |
| 5 | Is the condition refractory to intravenous (IV) bisphosphonate therapy or is there a clinical reason to avoid IV bisphosphonate therapy? | Yes | No |

| | |
|-----------|--|
| Comments: | |
|-----------|--|

By signing this form, I attest that the information provided is accurate and true as of this date and that the documentation supporting this information is available for review if requested by the health plan.

| | |
|--|--------------------|
| Prescriber (or Authorized) Signature: _____ | Date: _____ |
|--|--------------------|